A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
Latest Information Update: 20 Sep 2024
At a glance
- Drugs H 1337 (Primary) ; Timolol
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors D. Western Therapeutics Institute
Most Recent Events
- 13 Sep 2024 Status changed from active, no longer recruiting to completed.
- 27 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2023 Status changed from not yet recruiting to recruiting.